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Abstract
Cardiac fibroblasts are the major producers of extracellular matrix (ECM) to form infarct scar. We hypothesized that fibro-
blasts undergo a spectrum of phenotype states over the course of myocardial infarction (MI) from early onset to scar forma-
tion. Fibroblasts were isolated from the infarct region of C57BL/6J male mice (3–6 months old, n = 60) at days 0 (no MI 
control) and 1, 3, or 7 after MI. Whole transcriptome analysis was performed by RNA-sequencing. Of the genes sequenced, 
3371 were differentially expressed after MI. Enrichment analysis revealed that MI day 1 fibroblasts displayed pro-inflam-
matory, leukocyte-recruiting, pro-survival, and anti-migratory phenotype through Tnfrsf9 and CD137 signaling. MI day 3 
fibroblasts had a proliferative, pro-fibrotic, and pro-angiogenic profile with elevated Il4ra signaling. MI day 7 fibroblasts 
showed an anti-angiogenic homeostatic-like myofibroblast profile and with a step-wise increase in Acta2 expression. MI day 
7 fibroblasts relied on Pik3r3 signaling to mediate Tgfb1 effects and Fgfr2 to regulate PI3K signaling. In vitro, the day 3 MI 
fibroblast secretome stimulated angiogenesis, while day 7 MI fibroblast secretome repressed angiogenesis through Thbs1 
signaling. Our results reveal novel mechanisms for fibroblasts in expressing pro-inflammatory molecules and regulating 
angiogenesis following MI.
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Introduction
Myocardial infarction (MI) occurs when coronary blood 
flow to the left ventricle (LV) is blocked for a sufficient dura-
tion to result in tissue necrosis. The cardiac wound healing 
response involves robust inflammation, extracellular matrix 
(ECM) remodeling, revascularization, and scar formation 
[23, 41, 53]. While the cardiac fibroblast serves a baseline 
homeostasis role or transforms to an activated myofibroblast 
in response to injury, intermediary phenotypes exist, and 
fibroblasts display a range of phenotypes in response to indi-
vidual in vitro stimuli [1, 61]. For example, cardiac fibro-
blasts stimulated with lipopolysaccharide show increased 
pro-inflammatory cytokine production and decreased col-
lagen synthesis [37, 59]. Fibroblasts stimulated with trans-
forming growth factor (TGF)β1 increase collagen synthesis 
and differentiate to a myofibroblast phenotype [62, 65].
Angiogenesis is the formation of new microvessels that 
sprout from pre-existing endothelial cells to re-establish 
blood flow to the infarcted myocardium, making it a prom-
ising therapeutic strategy for MI [7]. While endothelial cells 
can self-activate to promote proliferation after injury, other 
cell types such as macrophages mediate endothelial cell 
activation and the formation of new capillaries [7]. Anti-
inflammatory macrophages secrete factors that promote 
proliferation of both fibroblasts (TGFβ1) and endothelial 
cells (vascular endothelial growth factor, VEGF) to form 
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granulation tissue [3]. The role of cardiac fibroblasts in reg-
ulating angiogenesis in the heart has not been thoroughly 
investigated.
The goals of this study were to combine transcriptomics 
and cell physiology to provide a map of fibroblast pheno-
types in response to MI and to determine the mechanisms 
of the infarct fibroblast in mediating inflammation and 
angiogenesis. We analyzed transcriptomic changes at MI 
days 1, 3, and 7 which represented the early inflammatory, 
proliferative, and maturation phases of cardiac wound heal-
ing. We hypothesized that fibroblasts undergo a spectrum 
of phenotype states over the course of MI from early onset 
to scar formation. This cell phenotype range begins with 
resident cells maintaining homeostasis and ends with a new 
type of resident cell that maintains the MI reset in homeo-
stasis. To our knowledge, this is the first study to detail the 
full transcriptome changes that occur in cardiac fibroblasts 
to mediate MI inflammation and angiogenesis.
Materials and methods (detailed methods 
in supplemental materials)
Animal use
All procedures involving animals were approved by the Insti-
tutional Animal Care and Use Committee at the University 
of Mississippi Medical Center. A total of 69 C57BL/6 J 
adult (3–6 months old) male mice were included, 60 for 
transcriptome analysis, and 9 for multiplex immunofluores-
cence. Groups were randomly assigned prior to the surgeries 
by one investigator (KYDP) and another investigator (YM) 
performed the majority of surgeries. To reduce animal use as 
recommended by the National Centre for the Replacement, 
Refinement, and Reduction of Animals in Research [46], the 
fibroblasts used in this study were obtained from a subset of 
the same mice used for macrophage isolation [36].
Coronary artery ligation
To produce permanent MI, mice underwent coronary artery 
ligation surgery as described previously and according to 
the Guidelines for Experimental Models of Ischemia and 
Infarction [10, 21, 24, 31, 36]. Mice were anesthetized with 
2% isoflurane, intubated, and ventilated. The left coronary 
artery was ligated with 8-0 suture, and MI was confirmed 
by LV blanching and ST-segment elevation on the EKG. 
Buprenorphine (0.5 mg/kg body weight) was administered 
to the mice immediately before surgery. Mice not receiv-
ing surgery were used as no MI controls (day 0), as sham-
operated mice do not differ in physiology or inflammatory 
gene expression from non-surgical controls [18].
Echocardiography and necropsy
LV physiology was determined by transthoracic echocar-
diography (Vevo 2100, VisualSonics; Toronto, CA) as 
described before and according to the Guidelines for Meas-
uring Cardiac Physiology in Mice [10, 21, 27, 31, 36]. Mice 
were anesthetized under 1–2% isoflurane, and both long- and 
short-axis images were obtained. Measurements were taken 
on the terminal day and were averaged from three cardiac 
cycles for each mouse. Following imaging, the hearts were 
removed and the left ventricle (LV) divided into remote and 
infarct (which included border zone) regions. Each region 
was separately weighed for infarct area estimation.
Isolation of LV infarct fibroblasts
LV fibroblasts were isolated from the infarct by immuno-
magnetic separation as described previously [10, 21, 36]. 
Excised LV tissue was rinsed and immediately minced and 
digested by collagenase II (Worthington; Lakewood, NJ) 
and DNase solution in Hanks-buffered saline solution. After 
digestion, a single-cell suspension was generated and filtered 
through a 30 µm pre-separation column. Cell suspensions 
were incubated at 4 °C for 10 min with an anti-Ly6G-biotin 
antibody followed by anti-biotin microbeads contained in 
the anti-Ly-6G microbead kit (#130-092-332; Miltenyi Bio-
tech; Bergisch Gladbach, Germany) to remove neutrophils. 
Cells were incubated with anti-CD11b-microbeads (Miltenyi 
#130-049-601) for 15 min to remove macrophages. Cells 
conjugated to the antibody microbeads were separated by 
magnetic columns (Miltenyi #130-042-201), and the efflu-
ent (Ly6G- and Cd11b- cells) was plated in T25 flasks in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS) and 1× antibiotic–anti-
mycotic solution (Gibco #15240-062). Fibroblasts at passage 
2 were used for RNA-Sequencing (RNA-seq), proliferation 
assays, and secretome collection; fibroblasts at passage 3 
were used for the migration assay. For cell and secretome 
collection, 4 ×  104 cells were seeded into 6-well plates and 
grown to 80% confluence in DMEM supplemented with 10% 
fetal bovine serum (FBS). Cells were incubated in DMEM 
with 0.1% FBS for 16 h, after which the media was replaced 
with fresh media and collected after 24 h. The cell fraction 
was collected for RNA-seq, and the secretome was collected 
for mass spectrometry and immunoblotting examination and 
endothelial cell stimulation experiments.
RNA‑seq
Fibroblasts were pooled to obtain three biological repli-
cates for each day. Sample sizes were: day 0-n = 10 mice/
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pool; day 1-n = 3–6 mice/pool, day 3-n = 3 mice/pool, and 
day 7-n = 2–3 mice/pool. Whole transcriptome analysis 
was performed as described previously [21, 31, 36]. RNA 
was extracted using the Pure Link RNA Mini Kit (Ambion; 
Foster City, CA, USA) according to the manufacturer’s 
instructions and assessed for quality control parameters 
of minimum concentration and size range. The cDNA 
libraries were developed using the TruSeq Total Stranded 
RNA with RiboZero Kit (Ambion), Set-A, quantified with 
the Qubit System (Invitrogen; Carlsbad, CA, USA), and 
assessed for quality and size with the Experion DNA 1 K 
Chip (Bio-Rad; Hercules, CA). All samples passed qual-
ity control standards of minimum concentration and RNA 
Quality Indicator > 9, with discrete 18S and 28S bands. 
The library of n = 12 pooled samples was sequenced using 
the NextSeq 500 High Output Kit (300 cycles, paired 
end 100 bp) on the Illumina NextSeq 500 platform (Illu-
mina; San Diego, CA, USA). Sequenced reads and Fastq 
sequence files were used to align reads to the reference 
genome USCS-GRCm38/mm10 in the RNA-Seq Align-
ment Application with STAR aligner using Illumina Cloud 
Computing Platform. Fragments Per Kilobase of transcript 
per Million mapped reads (FPKM) values of reference 
genes and transcripts were generated using Cufflinks 2.
Bioinformatic analyses
Analyses tools available in the online resource Metabo-
analyst 3.0 (http://www.metab oanal yst.ca/) and GraphPad 
Prism were used for graphical and statistical analyses. 
FPKM values were uploaded into Metaboanalyst, and one-
way ANOVA with Tukey’s post hoc test was performed 
to determine differentially expressed genes (defined as 
p < 0.05). Important feature analysis was used to identify 
the top five ranked genes at each MI day. Partial least-
squares determinant analysis (PLS-DA) and heat map-
ping were used to evaluate changes in signaling genes. 
To assess differential expression at individual MI days, 
volcano plot analysis was performed comparing the MI 
day to day 0, with a cut-off fold-change threshold of > 1.2 
and p < 0.05. A gene correlation network was constructed 
using the software Graphia Pro (Kajeka; Edinburgh, UK) 
and a Pearson correlation threshold of r > 0.95. The result-
ant graph was subjected to Markov clustering analysis to 
identify co-expression modules. Enrichment analysis for 
differentially expressed genes from each cluster was per-
formed using Enrichr (http://amp.pharm .mssm.edu/Enric 
hr/) for both Panther Pathways and Gene Ontology (GO) 
Biological Processes. For MI signaling profiles, we per-
formed partial least-squares discriminant analysis (PLS-
DA) and heat mapping for receptors and intracellular sign-
aling genes.
RT‑PCR validation
Quantitative RT-PCR was used as a secondary validation 
of gene expression in the same samples used for RNA-Seq. 
Extracted RNA from cardiac fibroblasts was used to syn-
thesize cDNA with the High Capacity RNA-to-cDNA kit 
(Applied Biosystems 4387406), and RT-PCR was performed 
using the Taqman Gene Expression Assay (Applied Bio-
systems). Acta2, Col3a1, and Postn were chosen as known 
fibroblast markers, while Cx3cl1 and Mmp14 were cho-
sen to represent genes differentially expressed at different 
time points. Gene expression was calculated as  2−ΔCt to the 
housekeeping gene Hprt1 [26]. RT-PCR experiments were 
performed according to the Minimum Information for Publi-
cation of Quantitative Real-Time PCR Experiments (MIQE) 
with the exception that Hprt1 was used as the housekeeping 
gene [19].
Fibroblast cell physiology
Fibroblast proliferation was assessed by bromodeoxyuridine 
(BrdU) enzyme-linked immunosorbent assay (Roche Diag-
nostics #11647229001; Mannheim, Germany) as described 
previously using the same pooled samples for RNA-Seq at 
passage 2 [10, 21]. Cells were seeded into 96-well plates 
and 24 h later serum starved for 16–18 h. The plate was 
then incubated for 24 h in DMEM and antibiotics with 
either 0.1% or 10% FBS. Cells were incubated with BrdU 
(10 µM), fixed, and incubated with an anti-BrdU antibody. 
Absorbance at 370 nm and 492 nm was determined using a 
microplate reader, with measurements taken at 30 min and 
subtracting the limit value of 492 nm from 370 nm. Fibro-
blast migration was determined by electrical-cell impedance 
sensing (ECIS; Applied Biophysics) cells as described previ-
ously [10, 21]. Cells (4 ×  104) were plated in 96-well plates 
with gold-film surface electrodes and cultured for 48 h. 
Cell monolayers were wounded, and rate of migration was 
assessed as change in impedance over time.
Multiplex immunofluorescence
LV mid-sections were fixed in 10% zinc-buffered forma-
lin, paraffin-embedded, and sectioned at 5 µm. Slides were 
deparaffinized and rehydrated. Immunohistochemical stain-
ing was performed using the Opal 7-color Automation Kit 
(Perkin Elmer #NEL80100KT; Boston, MA, USA). Sections 
were stained with the following primary antibodies conju-
gated to Opal fluorophores: PDGFRα (1:100, R&D Systems; 
#AF1062; Minneapolis, MN) conjugated to Opal 520, and 
CX3CL1 (1:500; R&D #MAB571), CCL5/RANTES (R&D 
#AF478), VEGF (Abcam #ab51745), or thrombospondin 1 
(Thbs1; 1:100; R&D Systems #AF3074) conjugated to Opal 
650. Nuclei were counterstained with DAPI. Opal 520 and 
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650 fluorophores were visualized with FITC and Cy5 chan-
nels, respectively. Images were obtained using the Mantra 
System (Perkin Elmer) and quantified using inForm software 
(Perkin Elmer).
Mass spectrometry
Fibroblast secretomes (500 µl) from day 0 or MI day 7 were 
cleaned using Sep-Pak Vac C18 cartridge (Waters, Milford, 
MA), and then reduced, alkylated, and trypsin-digested into 
peptides. The peptides were cleaned again using another 
Sep-Pak Vac C18 cartridge (Waters, Milford, MA) and ana-
lyzed label-free by liquid chromatography–tandem mass 
spectrometry using a Q Exactive (ThermoFisher, Waltham, 
MA, USA). A 15 cm × 75 μm C18 column (5 μm particles 
with 100 Å pore size) was used and the nano-UPLC ran at 
300 nL/min with a 150-min linear acetonitrile gradient (from 
5 to 35% B over 150 min; A = 0.2% formic acid in water; 
B = 0.2% formic acid in 90% acetonitrile). Tandem mass 
spectrometry (MS/MS) was set with an exclusion of 25 s, 
and the samples were run with high-energy collisional dis-
sociation fragmentation at normalized collision energy of 30 
and an isolation width of 2 m/z. The resolution setting was 
70,000 for target values of the MS at 1e6 ions and in MS2 
at resolution setting of 17,500 for  1x105 ions. The identified 
peptides were quantified using spectral counting and total 
spectral counts of each sample were used for normalization, 
and a sample report was generated in Scaffold version 4.8.7 
(Proteome Software, Portland, OR). Data (quantitative val-
ues of normalized total spectra) were analyzed by t test. The 
mass spectrometry proteomics data have been deposited to 
the ProteomeXchange Consortium via the PRIDE partner 
repository with the dataset identifier PXD011778 [64].
Immunoblotting
Immunoblotting was performed according to the Guide-
lines for authors and reviewers on antibody use in physiol-
ogy studies [5]. Secretome (20 µl) was separated by 4–12% 
 Criterion™ XT Bis–Tris gels (Bio-Rad) and transferred 
to nitrocellulose membranes (Bio-Rad). Total protein was 
stained with MemCode™ Reversible Protein Stain Kit 
(Thermo Scientific #24580; Waltham, MA). Membranes 
were blocked for 1 h in 5% milk at room temperature and 
incubated with a primary antibody against Thbs1 (R&D 
Systems; #AF3074; 1:500) at 4 °C overnight. Recombinant 
Thbs1 (R&D Systems #7589-TH; 10 ng) was used as a 
positive control. Membranes were washed and incubated 
with secondary antibody (Vector #PI-1000; Malvern, PA, 
USA) at room temperature for 2 h. Images were detected 
using ECL Prime Western Blotting Detection Substrate 
(Amersham; Little Chalfont, UK). Protein expression was 
analyzed by densitometry using IQ-TL image analysis 
software (GE Healthcare; Waukesha, WI) and normalized 
to the total protein.
Angiogenesis assay
Mouse microvascular endothelial cells (Cell Biologics 
#C57-6024; Chicago, IL, USA; 2.5 ×  104 cells/well, n = 2 
technical replicates per condition) were seeded in 48-well 
plates coated with basement membrane extract  (Matrigel® 
BD #354230; Franklin Lakes, NJ, USA). Cells were stimu-
lated with either basal endothelial cell medium (CellBio-
logics #M1168), basal medium supplemented with 10% 
cardiac fibroblast secretome from the same samples used 
for RNA-Seq (n = 3 biological replicates), or endothelial 
growth medium (basal medium supplemented with VEGF, 
endothelial cell growth supplement, heparin, epidermal 
growth factor, hydrocortisone, l-glutamine, antibiotics, 
and FBS). Thbs1 was inhibited with a blocking antibody 
(10 µg/ml; Novus Biologicals #100-2059) as described 
previously [32]. As negative controls, endothelial cells 
were stimulated with the Thbs1 blocking antibody alone, 
an IgG1 isotype control (R&D #MAB002) alone, or basal 
medium diluted 1:10 with DMEM + 0.1% FBS. Images 
were acquired at 10X magnification following 22 h of 
stimulation. Angiogenesis variables were quantified using 
the ImageJ Angiogenesis Analyzer feature (http://image 
.bio.metho ds.free.fr/Image J/?Angio genes is-Analy zer-for-
Image J&artpa ge=2-6).
Statistics
Statistical analysis was performed according to the guide-
lines, Statistical Considerations in Reporting Cardiovas-
cular Research [25]. All experiments were performed 
and analyzed in a blinded design. Data are presented as 
mean ± SEM unless otherwise noted. Survival rate was 
analyzed by Kaplan–Meier survival analysis. For physiol-
ogy assessment, multiple group comparisons were made 
using one-way ANOVA followed by Newman–Keuls post 
hoc test. Statistics and bioinformatics for the RNA-seq 
are described above. RNA-seq comparisons to quantita-
tive RT-PCR were made by Pearson’s linear regression 
analysis. Cell physiology comparisons were analyzed by 
two-tailed unpaired t test or one-sample t test. A value of 
p < 0.05 was considered statistically significant.
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Results
Fibroblasts continually polarize over the MI 
spectrum
Proof of successful MI
Survival for the MI day 7 cohort was 52% (13/25), with 
58% of mortality (7/12) due to cardiac rupture assessed at 
autopsy (Online Resource 1a). Infarct area (percent of LVI 
mass to total LV mass) did not differ between days 1, 3, 
and 7 (Online Resource 1b), indicating uniform infarct sizes 
across times and in line with the immediate myocyte necro-
sis that occurs after MI. As expected, MI led to infarct LV 
wall thinning, dilation, and decreased fractional shortening 
(Online Resource 1c–f). This is similar to what we and oth-
ers have previously reported for mouse MI [9, 10, 21, 31, 
66, 73].
MI differential gene expression and enrichment
Of 23,487 genes sequenced, 175 were duplicates and 6374 
were removed either because all FPKM values were 0 or 
there were less than 3 replicates with values greater than 0 
for any one group, leaving 16,938 genes for analysis (Fig. 1a; 
Online Table 1a). The FPKM values for all genes are dis-
played in Online Table 1. Of these, 3371 were differentially 
expressed by one-way ANOVA with Tukey’s post hoc 
test (Fig. 1a, b). Cell-specific markers for fibroblasts were 
highly expressed, while markers for other cell types were 
nearly undetectable (Online Resource 2a). Acta2 expression 
positively correlated with time after MI (r = 0.70, p = 0.01; 
Online Resource 2b). By mass spectrometry analysis of the 
day 0 and MI day 7 fibroblast secretomes, collagen I alpha 
1 and 2 chains, secreted protein acidic and rich in cysteine 
(SPARC), and lysyl oxidase were significantly increased in 
the day 7 MI fibroblast secretome, while periostin showed no 
change (Online Resource 2b). Periostin gene expression was 
significantly increased in the LV infarct at days 1, 3, 5, and 7 
(Online Resource 2c). Our results indicate the fibroblast acti-
vation marker collagens and collagen cross-linking enzymes 
are regulated at the protein level in MI cardiac fibroblasts.
For RT-PCR confirmation, four of the five genes (all 
except MMP-14) showed strong correlations between RNA-
seq and RT-PCR (Online Resource 3). PLS-DA (Fig. 1c) 
indicated that each MI day was a separate cluster, with MI 
day 7 being the most separated from the day 0 no MI control. 
Significantly enriched pathways by Panther (all p < 0.05) are 
displayed in Fig. 1d. The top 15 genes ranked by important 
23,487 
genes 
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6,549 genes 
removed
16,938 
genes 
analyzed
Pathway 
Analysis
3,371 genes 
DE by 
ANOVA
(p<0.05)
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(a)
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Cholesterol biosynthesis
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Cadherin signaling
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Fig. 1  a Workflow for analyzing differential gene expression. Of 
23,487 genes sequenced, 175 were duplicates and 6,374 did not meet 
quality control criteria and were removed, leaving 16,938 for analysis. 
Of the remaining genes, 3,371 were differentially expressed by one-
way ANOVA with Tukey’s post test (p < 0.05). b Heat map display-
ing differentially expressed genes across the MI time course. c Partial 
least-squares discriminant analysis (PLS-DA) plot. MI day 1 showed 
overlap with day 0, while days 3 and 7 were unique. d Enrichment 
analysis (Panther) for significant pathways across the MI time course. 
e Top 15 genes ranked by feature analysis and relative expression 
across each day (red—high; green—low)
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gene feature analysis are displayed in Fig. 1e, with the top-
ranked gene being Thbs1.
By Venn diagram analysis of fold changes compared 
to day 0 with a fold-change cut-off of 1.2 and p < 0.05, 
(Fig. 2a), 387 genes were upregulated and 512 were down-
regulated at MI day 1, 553 were upregulated and 964 down-
regulated at MI day 3, and 672 upregulated and 868 down-
regulated at MI day 7. Very few of the top-ranked genes 
overlapped among days, with the majority being unique to 
only one time point (Fig. 2b). The top 5 genes at each MI 
day ranked by variable importance in projection coefficients 
are displayed in Fig. 2c.
PLS-DA analysis and heat mapping for intracellular sign-
aling genes (including FGF, IL-1, IL-4, MAPK, NFκB, PI3K, 
Smad, Socs, STAT, TGFβ1, and TNF) revealed that all MI 
days displayed unique signaling profiles compared to day 0, 
with MI days 1 and 3 showing the greatest overlap (Fig. 3a). 
By examining differentially expressed signaling genes in the 
heat map (Fig. 3b, c), day 0 fibroblasts use Pik3r4 and Stat5 
signaling, while MI day 1 fibroblasts use Tnfrsf9 (CD137) 
signaling to induce inflammation [20], MI day 3 fibroblasts 
use interleukin-4 receptor alpha (Il4ra) signaling to stimu-
late anti-inflammatory and pro-fibrotic wound healing [44], 
and MI day 7 fibroblasts use Pik3r3 signaling to mediate 
TGFβ1 effects [65] and Fgfr2 to regulate PI3K signaling 
[42].
Cell‑surface marker analysis
Using Enrichr, upregulated genes that encode for cell-sur-
face proteins were compared across MI days to determine 
genes that distinguish fibroblasts and MI day. A total of 28 
genes were selectively upregulated at MI day 1, 32 at MI day 
3, and 31 at MI day 7. A total of 314 genes were all elevated 
with MI and did not change across MI time, and these can be 
considered potential pan MI fibroblast cell-surface markers. 
The top 25 ranked genes for each time are listed in Online 
Table 2. Recent mapping of the human cardiac proteome 
across cell types revealed a number of novel cardiac fibro-
blast cell-surface markers, including Acvr1, Met, Npr3, and 
Ror1 [11]. Our results indicate that Met and Npr3 were not 
affected by MI, while Acvr1 and Ror1 were both upregulated 
at MI day 7. These results provide a framework for identi-
fying novel cardiac fibroblast cell-surface markers in the 
healthy and injured myocardium.
Cluster analysis of differentially expressed genes
We used Markov clustering of the gene correlation network 
to assess gene expression patterns over the MI time course. 
Differentially expressed genes fell into one of eight unique 
pattern clusters (Fig. 4a, b). Cluster 1 (276 genes) and 3 (156 
genes) both represented genes upregulated only at day 1. The 
top enriched processes (Fig. 4) for these two clusters were 
pentose phosphate pathway and cytokine/chemokine-medi-
ated inflammation, corroborating the results from Fig. 2a. 
Cluster 5 (88 genes) and 7 (49 genes) were increased at day 3 
only, and were enriched for cholesterol biosynthesis (cluster 
5) and cadherin signaling (cluster 7). Cluster 4 genes (109 
genes) were upregulated at day 3 and further increased at 
day 7, and were enriched for angiogenesis. Cluster 2 genes 
(161 genes) were upregulated at day 7, and were enriched 
for cadherin signaling.
Fig. 2  MI yields distinct time-
dependent gene expression 
profiles in cardiac fibroblasts. a 
Differentially expressed genes 
(upregulated or downregu-
lated) at each MI day. b Venn 
diagrams indicating expres-
sion overlap among MI days. c 
Important feature analysis for 
the top five upregulated genes at 
each MI day
Important gene features on individual days 
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Day 0 fibroblasts were homeostatic
Cardiac fibroblasts in the uninjured heart were not qui-
escent. Rather, they served as sentinel cells to maintain 
the homeostasis of the myocardium by producing replace-
ment ECM at low concentrations necessary for normal 
turnover [6]. We developed a list of pan fibroblast genes, 
which included genes that did not change across any of 
the times and ranked by FPKM value; the top 500 are 
shown in Online Table 3. Entering the top 500 ranked 
genes into the Mouse Gene Atlas (http://www.mouse atlas 
.org/) revealed close alignment with mouse embryonic 
fibroblasts and osteoblasts (Online Table 4). The major 
enriched pathways represent pathways that are highly 
active in fibroblasts, regardless of injury state, including 
integrin signaling and glycolysis. To characterize the day 
0 phenotype, we analyzed genes that were high only at 
day 0 (genes significantly decreased at all MI days, n = 63 
genes). By Panther analysis, day 0 genes were enriched 
for 5-hydroxytryptamine degradation, mannose metabo-
lism, and de novo pyrimidine ribonucleotide biosynthesis 
(Online Table 5).
MI day 1 fibroblasts demonstrated a pro‑inflammatory 
and leukocyte‑recruiting, pro‑survival, and anti‑migratory 
signature (Fig. 5, Online Table 6)
Upregulated and downregulated genes are displayed by 
volcano plot (Fig.  5a). By Panther pathway analysis, 
chemokine- and cytokine-mediated inflammation was a 
major upregulated pathway. Interestingly, while Tgfb1 
was increased at MI day 1 (Online Resource 4a), TGFβ 
signaling was downregulated (Fig. 5a). By GO pathway 
evaluation, regulation of T helper 17 cell lineage com-
mitment (i.e. Il23a), positive regulation of memory T cell 
differentiation, negative regulation of interleukin-10 pro-
duction, and positive regulation of macrophage chemo-
taxis (i.e., Ccl5, Csf1, and Cx3cl1) were upregulated 
biological processes (Online Table 6), indicating that MI 
day 1 fibroblasts provide leukocyte-recruiting signals to 
bring cells into the infarct region [68]. Out of ten apop-
tosis genes evaluated, only one, the anti-apoptotic Bcl2, 
was elevated at MI day 1 (Online Resource 4b), indicating 
pro-survival signaling. Fibroblast migration rates were sig-
nificantly decreased at MI day 1 (Fig. 5b), and expression 
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of migration-related genes Cthrc1, Fgf2, and Fzd2 was 
significantly decreased (Fig. 5c).
MI day 3 fibroblasts demonstrated a proliferative, 
pro‑fibrotic, and pro‑angiogenic signature
Upregulated and downregulated genes are plotted by vol-
cano plot (Fig. 6a). By Panther pathway analysis (Fig. 6b), 
integrin signaling (i.e. Fn1 and Itga5), cadherin signaling 
(Cdh2), and angiogenesis (i.e., Vegfa) were major upreg-
ulated pathways (Online Table 5). By GO analysis, ECM 
organization (i.e., Fn1 and Lox) and cell migration involved 
in sprouting angiogenesis and blood vessel endothelial cell 
migration (i.e. Slit2, Ephb4, and Vegfa) were major upregu-
lated biological processes (Online Table 6). Vegfa was sig-
nificantly increased only at MI day 3. MI Day 3 fibroblasts 
were more proliferative than day 0 (Fig. 6c). The increase 
in fibroblast proliferation after MI is similar to what we and 
others have shown [13, 54]. Of the ten proliferation markers 
examined (Fig. 6d), the recently identified maker of fibro-
blast proliferation Ckap4 was elevated at MI day 3 [14]. In 
addition, expression of Casp3 was significantly reduced at 
MI day 3 (Online Resource 4b), indicating continuation of 
the anti-apoptotic and pro-survival signature. We observed 
robust changes in genes encoding for cholesterol biosyn-
thesis (decreased at MI day 1 and increased at MI day 3). 
The increase in genes involved in cholesterol metabolism 
coincide with increased cell proliferation at MI day 3, which 
requires cholesterol biosynthesis to support new cell mem-
brane formation, proper function of new cell membrane pro-
teins, and lipid rafts/caveolae to mediate signaling pathways 
involved in cell proliferation [2, 51].
MI day 7 fibroblasts demonstrated a homeostatic‑like, 
anti‑angiogenic signature
Upregulated and downregulated genes are plotted by vol-
cano plot (Fig. 7a). By Panther pathway analysis (Online 
Table 5), cadherin signaling (i.e., Cdh11) and angiogen-
esis (i.e., Pdgfc, and Thbs1) were major upregulated path-
ways. By GO analysis (Online Table 6), positive regu-
lation of bone mineralization (i.e., Grem1 and Tgfb3), 
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wound healing, and regulation of endothelial cell chemo-
taxis (Sema5a, Tmsb4x, and Thbs1) were major upregu-
lated processes. At MI day 7, the majority of fibroblasts 
are transdifferentiated into the myofibroblast phenotype 
[1]. Several myofibroblast-related genes were elevated 
only at MI day 7 (Online Resource 4a), including Cdh2 
(N-cadherin) [48, 58], Cdh11 (cadherin-11) [53], Itga11 
(integrin alpha-11) [1, 57], Timp1 and Timp3 [56], and 
Tmsb4x (thymosin beta-4) [4]. We also found that Wt1 
and Twist1, markers of epicardial cell origin [52], were 
increased at day 7 (Online Resource 4c). Thbs1 was the 
highest ranked feature for differentially expressed genes 
by one-way ANOVA, being 3.2-fold increased at MI day 
7 over day 0. By MI day 7, the fibroblast signature was 
moving towards a homeostatic-like phenotype, returning 
towards the new baseline established by the beginning for-
mation of the infarct scar.
As Thbs1 is a potent inhibitor of angiogenesis, we 
investigated cardiac fibroblast-derived Thbs1 as a potential 
factor regulating MI angiogenesis. Platelet-derived growth 
factor (PDGF) receptor alpha (PDGFRα)-positive cardiac 
fibroblasts demonstrated robust staining in the infarcted 
myocardium at MI day 7 relative to day 0 (Fig. 7c) con-
sistent with other reports [15, 34, 35, 45]. Thbs1 immu-
nostaining in cardiac fibroblasts (PDGFRα + cells) was 
significantly increased in day 7 infarcts (Fig. 7c). By 
immunoblotting, Thbs1 significantly increased in the 
secretome from isolated day 7 fibroblasts, indicating that 
MI day 7 fibroblasts actively secrete Thbs1 (Fig.  7d). 
CX3CL1 and CCL5 at MI day 1 and VEGF at MI day 3 
did not localize to fibroblasts within the infarct, confirm-
ing that these proteins were secreted and not intracellular 
(Online Resource 6).
MI fibroblast dampening of angiogenesis 
is Thsb1‑dependent
As angiogenic factors were differentially expressed after MI 
(Online Table 6), we investigated the effects of the MI fibro-
blast secretome on endothelial cell tube formation in vitro. 
The day 0 and MI day 3 secretomes stimulated angiogenesis, 
as assessed by increased total length, total branching length, 
total segment length, number of pieces, number of meshes, 
and number of junctions relative to basal media (Fig. 8). MI 
day 7 secretome decreased angiogenic variables relative to 
day 0, indicating that MI day 7 fibroblasts shut off angio-
genesis. To determine whether Thbs1 explained the day 7 
secretome effects on endothelial cells, Thbs1 was inhibited 
with a blocking antibody. Inhibition of Thbs1 reduced the 
effect of the day 7 secretome on angiogenesis variables, 
indicating that the inhibitory effect of the day 7 secretome 
on angiogenesis was Thbs1-dependent. Thbs1 inhibition did 
not alter the effects of the day 0 or MI day 3 secretome, 
and the Thbs1 blocking antibody alone control, IgG1 iso-
type antibody control, or the basal media diluted 1:10 with 
DMEM and 0.1% FBS media only control did not show any 
differences.
Discussion
Cardiac fibroblasts have been implicated in MI remodeling 
and scar formation [15, 16, 33]. The goals of this study were 
to map the phenotypes of cardiac fibroblasts over the MI 
wound healing period and to explore new roles for fibro-
blasts in regulating inflammation and angiogenesis. The key 
findings were as follows: 1) day 0 no MI cardiac fibroblasts 
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served as sentinel cells to actively maintain myocardial 
homeostasis; 2) cardiac fibroblasts underwent distinct 
transcriptomic changes at MI days 1, 3, and 7, with day 1 
fibroblasts showing a pro-inflammatory signature, day 3 
fibroblasts showing a proliferative, reparative, and pro-angi-
ogenic profile, and day 7 fibroblasts showing homeostatic-
like features and negatively regulating angiogenesis; and 3) 
the negative regulation of angiogenesis by day 7 fibroblasts 
occurred through Thbs1 signaling. Our results provide new 
insights into fibroblast phenotypes across the MI spectrum, 
with an emphasis on the roles of fibroblasts in regulating 
inflammation and angiogenesis (Fig. 9).
Identifying pan cell-surface markers for all cardiac fibro-
blasts has been a considerable challenge [6, 13, 14, 16, 17, 
28]. Furthermore, a map of cell-surface markers across the 
MI injury state is lacking, as fibroblasts may increase or 
decrease marker expression in response to the changing 
microenvironment. Recent studies have identified novel 
markers in human cardiac fibroblasts from non-injured 
hearts, including the tyrosine kinase Ror1 and the activin 
receptor Acvr1 [11]. Our data validate these findings, as 
fibroblasts expressed both genes at every time point exam-
ined. The selective upregulation at MI day 7 indicates that 
these two genes may be particularly useful in identifying 
fibroblasts at MI day 7, when peak myofibroblast activation 
occurs [13]. Our findings provide a framework for identify-
ing both novel constitutive and inducible markers.
In the absence of injury, the cardiac fibroblast is the 
major cell type producing and maintaining the ECM. Car-
diac fibroblasts also support electro-chemical coupling, 
myocyte hypertrophy, and maintenance of the vasculature 
[17, 40]. Integrin signaling was the major enriched process 
for the pan fibroblast phenotype and was also enriched 
at MI days 3 and 7, indicating that MI fibroblasts selec-
tively express integrins to adapt to the changing ECM 
environment. Integrin switching includes Itga5, the major 
fibronectin-binding integrin, at MI day 3, and Itga11, the 
major collagen-binding integrin, at MI day 7 [1]. Inflam-
mation mediated by chemokine/cytokine signaling was 
enriched in the basal phenotype and at MI days 1 and 7, 
indicating that fibroblasts cross talk with resident immune 
cells regardless of injury state [29]. The day 0 secretome 
stimulated tube formation in vitro, indicating that fibro-
blasts in the uninjured heart play an active role in promot-
ing a healthy vasculature.
At MI day 1, fibroblasts displayed an inflammatory signa-
ture, consistent with other reports that fibroblasts initiate and 
contribute to inflammation following injury [22, 38]. CCL5 
and CX3CL1 are pro-inflammatory chemoattractants for 
monocytes and neutrophils [68]. Cardiac fibroblasts produce 
CX3CL1 in response to interferon γ stimulus [43]. Expres-
sion of Il23a, a pro-inflammatory cytokine that activates T 
helper 17 cells, was also increased at MI day 1 [67]. Colony 
stimulating facor-1 is critical for macrophage recruitment 
after MI [69]. TGFβ1 is an important anti-inflammatory 
cytokine that promotes fibroblast activation to myofibro-
blasts. TGFβ signaling was a major downregulated process, 
indicating that MI day 1 fibroblasts are unresponsive to 
increased TGFβ1 expression. Our results indicate that, in 
addition to other cell sources, fibroblasts are a source of pro-
inflammatory chemokines and cytokines to recruit inflam-
matory cells to the infarct region. Bcl2 was highly increased 
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(inputs, outputs, signaling path-
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at MI day 1, indicating that fibroblasts respond to ischemia 
by promoting cell survival signaling [13].
At MI day 3, fibroblasts showed a proliferative, pro-
fibrotic, and pro-angiogenic profile. Cholesterol biosyn-
thesis, a major upregulated process at day 3, is important 
in supporting cardiac fibroblast proliferation. Treatment of 
mice with simvastatin, a potent inhibitor of cholesterol bio-
synthesis, decreases LV collagen deposition and fibroblast 
activity after MI [55], and in vitro, simvastatin induces car-
diac fibroblast apoptosis, with a stronger effect on quiescent 
fibroblasts than activated myofibroblasts [8]. In line with 
these results, cholesterol biosynthesis was elevated at MI 
day 3, at which point fibroblasts were highly proliferative 
[13]. Thus, cholesterol biosynthesis may be required for MI 
fibroblast proliferation during the early granulation phase 
prior to scar formation and maturation.
MI day 3 fibroblasts showed a pro-angiogenic profile. 
Cardiac fibroblasts secrete several factors that regulate angi-
ogenesis, including VEGF [40, 60, 71, 72]. The positive 
regulation of angiogenesis at MI day 3 coincides with the 
peak of vessel formation and endothelial cell proliferation in 
the mouse, indicating that fibroblasts are a significant in vivo 
contributor to endothelial cell activation [63].
At MI day 7, fibroblasts displayed a homeostatic-like, 
anti-angiogenic signature. The epicardial cell markers 
Wt1 and Twist1 were significantly increased, consistent 
with other reports, indicating that MI day 7 fibroblasts are 
derived from epicardial progenitors that underwent epi-
thelial-to-mesenchymal transition [13, 47, 52]. In contrast 
to MI day 3, day 7 fibroblasts showed an anti-angiogenic 
profile. Fibroblast-derived factors can inhibit angiogenesis 
[30]. Our results suggest that day 7 fibroblasts may inhibit 
angiogenesis by altering the balance between pro-angiogenic 
(Vegfa) and anti-angiogenic (Cxcl14, Sema3a, Lypd1, and 
Thbs1) soluble mediators. Thbs1 has been heavily impli-
cated as a potent inhibitor of angiogenesis, mainly through 
pro-apoptotic and anti-VEGF actions on cardiac microvascu-
lar endothelial cells [71]. Thbs1 expression is induced in the 
infarcted heart by macrophages, platelets, and fibroblasts, 
peaking 24 h and remaining elevated as long as 28 days after 
MI in the rat heart [12, 50, 70]. Mice lacking Thbs1 show a 
prolonged inflammatory response and expansion of granula-
tion tissue following MI [12]. Our results indicate that car-
diac fibroblasts secrete Thbs1 at day 7 but not day 3, and 
that blocking Thbs1 reverses the anti-angiogenic properties 
of the MI day 7 secretome, indicating that fibroblast-derived 
Thbs1 tempers excessive angiogenesis.
Fibroblasts from day 0 healthy hearts potently stimulated 
angiogenesis, indicating that rather than being quiescent, 
fibroblasts in the healthy heart actively support angiogenesis 
and vessel homeostasis. Our results indicate a dichotomous 
role in fibroblast regulation of angiogenesis following MI 
injury, as day 0 and day 3 fibroblasts promoted angiogenesis, 
while day 7 fibroblasts show decreased angiogenic poten-
tial. Angiogenesis is typically considered beneficial for MI 
remodeling and correlates with better outcomes [31], thus 
targeting cardiac fibroblasts could be a potential therapeutic 
strategy to improve MI angiogenesis. MI day 7 fibroblasts 
may temper excessive and uncontrolled angiogenesis that 
could otherwise perturb proper scar formation [49]. Anti-
inflammatory and pro-reparative resident macrophage and 
circulating monocyte populations promote angiogenesis in 
the MI heart. It is possible that macrophages are the predom-
inant cell types in the MI heart that promote angiogenesis, 
while fibroblasts dial up or down as needed [39]. In addition 
to inhibiting angiogenesis, Thbs1 promotes the resolution 
of inflammation, suggesting that anti-inflammatory signals 
such as TGFβ1 may induce Thbs1 expression and promote 
anti-angiogenic actions during scar maturation [12].
Our results reveal that some concepts of classical fibro-
blast activation are in play after MI, while others have been 
preconceived ideas. Of note, we did not observe the expected 
increase in the myofibroblast marker Postn in MI fibroblasts. 
Periostin gene or protein expression did not change after MI 
in isolated fibroblasts, while gene expression did increase 
in the LV infarct at days 1, 3, 5, and 7. A recent report has 
shown increased Postn in the Tcf21+ subpopulation of car-
diac cells examined [13], indicating that a subset of fibro-
blasts (Tcf21+ cells) and non-fibroblast cells (e.g., smooth 
muscle cells and macrophages) are the source of periostin. 
We recently reported on the MI macrophage polarization 
time course [36]. Tcf21 was expressed in no MI resident car-
diac macrophages at 25–50-fold higher levels than MI days 
1, 3, or 7 macrophages and lower expression than fibroblasts 
(all p < 0.01), revealing fluidity in cell marker expression 
across cell types (fibroblasts and macrophages) and across 
MI times. We evaluated the total fibroblast pool (all fibro-
blasts adhering to culture dishes), indicating that periostin 
is a selective marker for a subset of cells. Despite culturing, 
our cells retained the features of myofibroblast activation 
including increased collagen, SPARC, and lysyl oxidase 
secretion. Our results reveal that, rather than a binary on or 
off pattern, Acta2 gene expression actually shows a continual 
increase over time (linear regression correlation coefficient 
r = 0.70, p = 0.01), indicating a persistent shift in time to the 
myofibroblast phenotype. Based on our evaluation, fibro-
blasts retained the in vivo MI phenotype in vitro through 
passage 3.
In conclusion, cardiac fibroblasts show distinct transcrip-
tomic profiles at different time points over the first week 
of MI wound healing. Our findings provide novel insights 
into the potential mechanisms and pathways that regulate 
fibroblast physiology during the wound healing phases of 
cardiac remodeling. Overall, our work suggests that atten-
tion to temporal profiles should be given when considering 
interventions that target fibroblasts.
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